Zhitong Finance App News, Guangshengtang (300436.SZ) announced that the company plans to jointly invest in the establishment of Guangfulai (Beijing) International Biotechnology Co., Ltd. (“Guangfulai”) with the related party Fuzhou Aotai Phase 9 Investment Partnership (“Aotai Phase 9”). Guangfulai's registered capital is 50 million yuan, of which the company plans to invest 35 million yuan in currency, accounting for 70% of Guangfulai's registered capital; Aotai Phase IX plans to invest 15 million yuan in monetary terms, accounting for 30% of Guangfulai's registered capital.

An affiliate, Aotai Phase 9, proposes to be an employee shareholding platform. Mr. Huang Fuhu, the company's director and deputy general manager, will first pledge the capital to establish Aotai Phase 9 as a general partner. Mr. Huang Fuhu accounts for 99% of Aotai Phase 9's investment and acts as an executive partner.

According to the announcement, Guangfulai will focus on expanding the international business areas of the company's pharmaceuticals, especially anti-coronavirus drugs, to enhance the company's future growth potential, market competitiveness and profitability, promote the development and growth of the company's international business scale, and further enhance the company's comprehensive strength.